TAC1 and glioblastoma: Patients with recurrent glioblastoma multiforme were treated with 1–7 doses of approx. 2 GBq 213Bi-DOTA-Substance P or 1–4 doses of 10 MBq 225Ac-DOTAGA-Substance P at two-month intervals.